Hikma advances its epinephrine nasal spray with multi-market regulatory filings

Regulatoryepinephrine nasal sprayPositive

AI Analysis

Summary

Hikma Pharmaceuticals announces that regulatory submissions for its epinephrine nasal spray for emergency treatment of anaphylaxis have been accepted for review by regulators in multiple markets.

Outcome Details

regulatory submissions accepted for review

Importance:6/10

Sentiment:

0.60

epinephrinenasal sprayanaphylaxisregulatory submissionmulti-market

Related Companies

$HIK.L

Read the original article

Published by PR Newswire Pharma on September 10, 2026 6:20 PM

Read Original